Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest knee osteoarthritis Stories

2013-10-30 08:31:39

- In a clinical trial, a single-dose of 40 mg of FX006 demonstrated enhanced therapeutic effects relative to the approved injectable dose of commonly available, immediate release steroid in patients with osteoarthritis of the knee - BURLINGTON, Mass., Oct. 30, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging clinical trial of the company's lead compound, FX006, were presented at the 2013 American College of Rheumatology Annual...

2013-10-10 23:29:46

Treatment Option Gives Hope to 20 Million Living With Osteoarthritis of the Knee Irvine, Calif. (PRWEB) October 10, 2013 A new study published in The American Journal of Orthopedics showed that 70 percent of patients who combined BioniCare, a non-invasive pulsed electrical stimulator from VQ OrthoCare®, with a joint unloading knee brace achieved significantly better clinical improvement, than with BioniCare stimulation treatment alone. The study consisted of more than 500 patients...

2013-10-10 23:29:43

Treatment Option Gives Hope to 20 Million Living With Osteoarthritis of the Knee Irvine, Calif. (PRWEB) October 10, 2013 A new study published in The American Journal of Orthopedics concluded that 70 percent of patients with osteoarthritis of the knee who were treated with BioniCare, a non-invasive pulsed electrical stimulator from VQ OrthoCare®, combined with an unloading brace for the knee, showed significant clinical benefit as determined by standard outcomes used to measure...

2013-09-30 08:29:21

GREENWOOD VILLAGE, Colo., Sept. 30, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced additional positive results from the SPRING study (clinicaltrials.gov NCT01839331) of Ampion((TM)) for the treatment of osteoarthritis of the knee (OAK). In this study of 329 patients, patients treated with a single intra-articular injection of Ampion((TM)) achieved a clinically meaningful reduction in pain. Ampio announced on August 14, 2013 that the SPRING study met its...

2013-09-06 08:22:26

Patients shown to achieve a clinically meaningful reduction in pain and increase in mobility PALO ALTO, Calif., Sept. 6, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce...

2013-08-21 16:25:07

Cost Savings are Good News as Aging Population Rapidly Increases Demand for Relief from Chronic Knee Pain ROSEMONT, Ill., Aug. 21, 2013 /PRNewswire-USNewswire/ -- The full impact of knee replacement surgery on both patients' lives and on society includes significant overall cost savings, according to a new study published in the Journal of Bone and Joint Surgery (JBJS). Researchers found that for the average patient undergoing knee replacement surgery, the expense of surgery is...

2013-08-21 10:22:13

Although a pooling of data from 12 studies showed a statistically significant association between use of lateral wedge insoles and lower pain in medial knee osteoarthritis, among trials comparing wedge insoles with neutral insoles, there was no significant or clinically important association between use of wedge insoles and reduction in knee pain, according to a study in the August 21 issue of JAMA. "Osteoarthritis of the knee is a common painful chronic disease whose prevalence is...

2013-08-14 08:29:50

Ampion Study Meets Primary Endpoint with High Statistical Significance; All Primary Study Objectives were Achieved GREENWOOD VILLAGE, Colo., Aug. 14, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results from the SPRING study (clinicaltrials.gov NCT01839331) of Ampion for the treatment of osteoarthritis of the knee (OAK). In this study of 329 patients, patients treated with a single intra-articular injection of Ampion achieved a clinically...

2013-07-22 12:26:07

PALO ALTO, Calif., July 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB:CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). "We are pleased that our patient enrollment is on schedule with our projected time to complete the Phase I clinical trial for Knee...

2013-07-21 23:00:23

A 40 Patient Clinical Trial using AdiStem PRP PhotoActivation is being planned in Australia following two initial case studies published in the “British Medical Journal”. One was on a 50 year old woman in Melbourne with left knee osteoarthritis and the other on a 38 year old man with traumatic chondral lesion of the left knee. Melbourne, Australia (PRWEB) July 22, 2013 A 40 Patient Clinical Trial using AdiStem PRP PhotoActivation is being planned in Australia following two initial...